Endlos Turbo Long 1,675 open end: Basiswert CureVac Rg

CureVac Announces Voting Results of General Meeting

^

Emittent / Herausgeber: CureVac / Schlagwort(e): Hauptversammlung

CureVac Announces Voting Results of General Meeting

24.06.2025 / 22:09 CET/CEST

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

CureVac Announces Voting Results of General Meeting

TÜBINGEN, Germany / BOSTON, USA - June 24, 2025 - CureVac N.V. (Nasdaq:

CVAC), a pioneering multinational biotech company developing a new class of

transformative medicines based on messenger RNA (mRNA), today announced the

voting results of the Company's Annual General Meeting.

The shareholders of the Company voted in favor of all proposals. These

proposals included the appointment of Axel Sven Malkomes as a member of the

Management Board, effective June 24, 2025. Additionally, Jean Stéphenne,

Debra Barker, Craig A. Tooman, as well as Klaus Schollmeier were reappointed

as members of the Supervisory Board, Mehdi Shahidi was appointed as a new

member of the Supervisory Board, effective June 24, 2025. KPMG Accountants

N.V. was reappointed as the external auditors for the financial year 2026.

A table containing tabulations of the votes casted is expected to be

released in the coming days.

About CureVac

CureVac (Nasdaq: CVAC) is a pioneering multinational biotech company founded

in 2000 to advance the field of messenger RNA (mRNA) technology for

application in human medicine. CureVac's mRNA platform incorporates a series

of novel technologies, designed to improve the efficacy, safety and

cost-effectiveness of mRNA therapeutics aimed at resulting in enhanced

immune responses at lower doses. Additionally, CureVac has developed LNPs,

which have been optimized for indication specific use across infectious

diseases and oncology. CureVac is leveraging mRNA technology, combined with

advanced omics and computational tools, to design and develop off-the-shelf

and personalized cancer vaccine product candidates. It also develops

programs in prophylactic vaccines and in treatments that aim to enable the

human body to produce its own therapeutic proteins. Headquartered in

Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium,

Switzerland, and the U.S. Further information can be found at

www.curevac.com.

CureVac Media and Investor Relations Contact

CureVac, Tübingen, Germany

T: +49 7071 9883-0

communications@curevac.com

Forward-Looking Statements of CureVac

This press release contains statements that constitute "forward looking

statements" as that term is defined in the United States Private Securities

Litigation Reform Act of 1995, including statements that express the

opinions, expectations, beliefs, plans, objectives, assumptions or

projections of CureVac N.V. and/or its wholly owned subsidiaries CureVac SE,

CureVac Manufacturing GmbH, CureVac Inc., CureVac Swiss AG, CureVac

Corporate Services GmbH, CureVac Belgium SA and CureVac Netherlands B.V.

(the "company") regarding future events or future results, in contrast with

statements that reflect historical facts. Examples include discussion of the

potential efficacy of the company's vaccine and treatment candidates and the

company's strategies, financing plans, cash runway expectations, timing of

various milestones, the impact of restructuring, growth opportunities and

market growth. In some cases, you can identify such forward-looking

statements by terminology such as "anticipate," "intend," "believe,"

"estimate," "plan," "seek," "project," "expect," "may," "will," "would,"

"could," "potential," "intend," or "should," the negative of these terms or

similar expressions. Forward-looking statements are based on management's

current beliefs and assumptions and on information currently available to

the company. However, these forward-looking statements are not a guarantee

of the company's performance, and you should not place undue reliance on

such statements. Forward-looking statements are subject to many risks,

uncertainties and other variable circumstances, including negative worldwide

economic conditions and ongoing instability and volatility in the worldwide

financial markets, ability to obtain funding, ability to conduct current and

future preclinical studies and clinical trials, the timing, expense and

uncertainty of regulatory approval, reliance on third parties and

collaboration partners, ability to commercialize products, ability to

manufacture any products, ability to implement our pipeline strategy,

possible changes in current and proposed legislation, regulations and

governmental policies, pressures from increasing competition and

consolidation in the company's industry, the effects of the COVID-19

pandemic on the company's business and results of operations, ability to

manage growth, ability to implement, maintain and improve effective internal

controls, reliance on key personnel, reliance on intellectual property

protection and the company's and the company's collaborators' ability to

obtain, maintain, defend and enforce such intellectual property, scope of

intellectual property protection, ability to provide for patient safety,

fluctuations of operating results due to the effect of exchange rates,

delays in litigation proceedings, different judicial outcomes and other

important factors discussed under the caption "Risk Factors" in the

company's annual report on Form 20-F filed with the U.S. Securities and

Exchange Commission (the "SEC") on April 11, 2025, as such factors may be

updated form time to time in its other filings with the SEC. Such risks and

uncertainties may cause the statements to be inaccurate and readers are

cautioned not to place undue reliance on such statements. Many of these

risks are outside of the company's control and could cause its actual

results to differ materially from those it thought would occur. The

forward-looking statements included in this press release are made only as

of the date hereof. The company does not undertake, and specifically

declines, any obligation to update any such statements or to publicly

announce the results of any revisions to any such statements to reflect

future events or developments, except as required by law.

For further information, please reference the company's reports and

documents filed with the SEC. You may get these documents by visiting EDGAR

on the SEC website at www.sec.gov.

---------------------------------------------------------------------------

Veröffentlichung einer Mitteilung, übermittelt durch EQS Group.

Medienarchiv unter https://www.eqs-news.com.

Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.

---------------------------------------------------------------------------

Sprache: Deutsch

Unternehmen: CureVac

Friedrich-Miescher-Str. 15

72076 Tübingen

Deutschland

EQS News ID: 2159904

Ende der Mitteilung EQS News-Service

---------------------------------------------------------------------------

°